Atossa Therapeutics (ATOS) Competitors $0.73 -0.01 (-0.73%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATOS vs. TECX, PHAT, RGNX, ALLO, BNTC, TKNO, ORKA, TRDA, HRTX, and MREOShould you be buying Atossa Therapeutics stock or one of its competitors? The main competitors of Atossa Therapeutics include Tectonic Therapeutic (TECX), Phathom Pharmaceuticals (PHAT), REGENXBIO (RGNX), Allogene Therapeutics (ALLO), Benitec Biopharma (BNTC), Alpha Teknova (TKNO), Oruka Therapeutics (ORKA), Entrada Therapeutics (TRDA), Heron Therapeutics (HRTX), and Mereo BioPharma Group (MREO). These companies are all part of the "pharmaceutical products" industry. Atossa Therapeutics vs. Tectonic Therapeutic Phathom Pharmaceuticals REGENXBIO Allogene Therapeutics Benitec Biopharma Alpha Teknova Oruka Therapeutics Entrada Therapeutics Heron Therapeutics Mereo BioPharma Group Tectonic Therapeutic (NASDAQ:TECX) and Atossa Therapeutics (NASDAQ:ATOS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, community ranking, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends. Do institutionals & insiders have more ownership in TECX or ATOS? 62.6% of Tectonic Therapeutic shares are held by institutional investors. Comparatively, 12.7% of Atossa Therapeutics shares are held by institutional investors. 9.2% of Tectonic Therapeutic shares are held by insiders. Comparatively, 7.6% of Atossa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is TECX or ATOS more profitable? Tectonic Therapeutic's return on equity of -35.53% beat Atossa Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tectonic TherapeuticN/A -35.53% -31.97% Atossa Therapeutics N/A -35.74%-33.51% Does the MarketBeat Community believe in TECX or ATOS? Atossa Therapeutics received 233 more outperform votes than Tectonic Therapeutic when rated by MarketBeat users. However, 100.00% of users gave Tectonic Therapeutic an outperform vote while only 65.50% of users gave Atossa Therapeutics an outperform vote. CompanyUnderperformOutperformTectonic TherapeuticOutperform Votes10100.00% Underperform VotesNo VotesAtossa TherapeuticsOutperform Votes24365.50% Underperform Votes12834.50% Do analysts prefer TECX or ATOS? Tectonic Therapeutic presently has a consensus price target of $72.40, indicating a potential upside of 224.84%. Atossa Therapeutics has a consensus price target of $7.13, indicating a potential upside of 880.06%. Given Atossa Therapeutics' higher probable upside, analysts plainly believe Atossa Therapeutics is more favorable than Tectonic Therapeutic.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tectonic Therapeutic 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Atossa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better earnings and valuation, TECX or ATOS? Atossa Therapeutics is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTectonic TherapeuticN/AN/A$12.16M-$6.53-3.41Atossa TherapeuticsN/AN/A-$30.09M-$0.21-3.46 Which has more volatility & risk, TECX or ATOS? Tectonic Therapeutic has a beta of 2.87, indicating that its share price is 187% more volatile than the S&P 500. Comparatively, Atossa Therapeutics has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Does the media refer more to TECX or ATOS? In the previous week, Tectonic Therapeutic had 4 more articles in the media than Atossa Therapeutics. MarketBeat recorded 12 mentions for Tectonic Therapeutic and 8 mentions for Atossa Therapeutics. Tectonic Therapeutic's average media sentiment score of 0.63 beat Atossa Therapeutics' score of 0.56 indicating that Tectonic Therapeutic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tectonic Therapeutic 4 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atossa Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryTectonic Therapeutic beats Atossa Therapeutics on 12 of the 16 factors compared between the two stocks. Get Atossa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATOS vs. The Competition Export to ExcelMetricAtossa TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$93.91M$6.60B$5.42B$7.70BDividend YieldN/A3.21%5.44%4.33%P/E Ratio-3.307.1022.2418.32Price / SalesN/A272.82396.86106.71Price / CashN/A65.6738.2034.62Price / Book1.006.496.834.25Net Income-$30.09M$142.72M$3.21B$247.59M7 Day Performance16.67%8.15%5.37%5.87%1 Month Performance-3.07%-7.63%-5.89%-3.97%1 Year Performance-51.53%-1.20%16.51%4.53% Atossa Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATOSAtossa Therapeutics1.8658 of 5 stars$0.73-0.7%$7.13+872.6%-50.5%$94.63MN/A-3.338Analyst ForecastAnalyst RevisionNews CoverageGap UpTECXTectonic Therapeutic2.7569 of 5 stars$17.86+10.5%$77.75+335.3%N/A$333.32MN/A-3.03120Analyst ForecastNews CoveragePHATPhathom Pharmaceuticals3.5886 of 5 stars$4.69-3.9%$22.17+372.6%-55.6%$326.60M$55.25M-0.82110Analyst ForecastRGNXREGENXBIO4.5879 of 5 stars$6.32+7.3%$31.88+404.4%-44.0%$316.74M$83.33M-1.26370News CoveragePositive NewsALLOAllogene Therapeutics2.9698 of 5 stars$1.44-1.0%$9.29+547.3%-52.2%$311.78M$22,000.00-0.92310News CoverageBNTCBenitec Biopharma2.4922 of 5 stars$13.13+4.0%$24.71+88.2%+99.1%$307.91M$80,000.00-8.7020Gap UpTKNOAlpha Teknova1.1391 of 5 stars$5.71+2.1%$8.50+48.9%+267.4%$305.13M$37.75M-7.72240News CoverageORKAOruka Therapeutics2.8907 of 5 stars$8.12+5.7%$39.86+390.9%N/A$304.02MN/A-1.30N/ATRDAEntrada Therapeutics2.8146 of 5 stars$7.93+0.4%$25.67+223.7%-32.4%$298.13M$210.78M4.99110Positive NewsHRTXHeron Therapeutics3.3448 of 5 stars$1.93+1.0%$5.67+193.6%-21.3%$294.00M$144.29M-10.72300News CoveragePositive NewsMREOMereo BioPharma Group1.851 of 5 stars$1.89-3.1%$7.71+308.2%-7.9%$293.23M$1M-31.5040News Coverage Related Companies and Tools Related Companies TECX Alternatives PHAT Alternatives RGNX Alternatives ALLO Alternatives BNTC Alternatives TKNO Alternatives ORKA Alternatives TRDA Alternatives HRTX Alternatives MREO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATOS) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Collapse Is Already HereWhen a system is about to fail, those trained to spot it often notice before anyone else. Tim Plaehn flew high...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored‘Wheels Are Falling Off’ the U.S. Stock MarketThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...Stansberry Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atossa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atossa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ATOS Stock Free ATOS Stock Alerts